Plain-English translation of NCT07330752 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This is one of the first times this treatment has been tested in people.
This is the first human trial of a new medical device called the A3-Shield implant, designed to treat small abdominal aortic aneurysms (weakened areas in the main blood vessel in your belly). The implant works by reducing the pressure and stress that your heartbeat normally puts on the aneurysm, which may help slow or stop it from getting bigger. This trial will check whether the implant is safe to use and whether the implantation procedure works well.
Right now, doctors can monitor small aneurysms or surgically replace them with artificial grafts, but there's no treatment that can actually stop them from growing on their own. This new device aims to fill that gap by stabilizing aneurysms early, before they become large enough to require major surgery with its associated risks.
You likely qualify if…
You likely don't qualify if…
You will undergo a catheter-based procedure to have the A3-Shield implant placed in your abdominal aorta—this is less invasive than traditional surgery. After the procedure, you will return to the hospital for scheduled follow-up visits to monitor how well the implant is working, check for any side effects, and measure whether your aneurysm remains stable. The trial involves 12 patients total and will track your progress over time using imaging and clinical assessments.
AI-generated summary from trial data · Aug 29, 2026 · Not medical advice
Uzbekistan